Jeena Sikho Lifecare Ltd

JSLL NSE Healthcare Pharmaceuticals
Microcap 250
₹511.85
-1.24%
Delayed · cached 15 min

Fair value analysis

JSLL
Jeena Sikho Lifecare Ltd
HealthcarePharmaceuticals
₹518.30
Close used for this calculation
₹488.18Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
66/100
Profitability25/25
Returns12/25
Balance Sheet19/25
Efficiency10/25
Growth12/25
Strong
Quality radar
66Prof.25/25Ret.12/25Eff.10/25B.Sht19/25Growth12/25

Consensus fair value

₹488.18
Near FV
▼ -5.8% against the close used
Model range ₹127.67 – ₹637.25
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹127.67Fair value₹488.18Bull₹637.25
FairClose
52-week traded range
52W low ₹492.2052W high ₹837.95

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Jeena Sikho Lifecare Ltd closed at ₹518.30, 6.2% above the consensus fair value of ₹488.18 drawn from 7 valuation models.

Financial DNA score 66/100 — Strong. P/E of 26.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹357.37
-31.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹127.67
-75.4%
√(22.5 × EPS × BVPS)
EPS=17.85, BVPS=40.59 · outside Graham range (P/E 26.9, P/B 12.8) — asset-light, treat as a rough floor
P/E Fair Value
₹637.25
+22.9%
EPS × 35.7x (sector P/E)
EPS=17.85, Sector P/E=35.7x
Peter Lynch (PEG)
₹446.25
-13.9%
EPS × Growth% (PEG = 1 is fair)
EPS=17.85, g=25%
EV/EBITDA
₹571.82
+10.3%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=3.97B
Reverse DCF
₹518.30
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 12.2% | Historical: 25%
Margin of Safety
₹280.57
-45.9%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=374.1, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.